The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study

Ponikowski, P. et al. (2015) The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. European Journal of Heart Failure, 17(3), pp. 329-339. (doi: 10.1002/ejhf.229) (PMID:25683972) (PMCID:PMC4413361)

[img]
Preview
Text
105052.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

555kB

Abstract

Aims: Anaemia and iron deficiency are constituents of the cardio-renal syndrome in chronic heart failure (CHF). We investigated the effects of i.v. iron in iron-deficient CHF patients on renal function, and the efficacy and safety of this therapy in patients with renal dysfunction.

Methods and results: The FAIR-HF trial randomized 459 CHF patients with iron deficiency (ferritin <100 µg/L, or between 100 and 299 µg/L if transferrin saturation was <20%): 304 to i.v. ferric carboxymaltose (FCM) and 155 to placebo, and followed-up for 24 weeks. Renal function was assessed at baseline and at weeks 4, 12, and 24, using the estimated glomerular filtration rate (eGFR, mL/min/1.73 m2), calculated from the Chronic Kidney Disease Epidemiology Collaboration (CKD–EPI) formula. At baseline, renal function was similar between groups (62.4 ± 20.6 vs. 62.9 ± 23.4 mL/min/1.73 m2, FCM vs. placebo). Compared with placebo, treatment with FCM was associated with an increase in eGFR [treatment effect: week 4, 2.11 ± 1.21 (P = 0.082); week 12, 2.41 ± 1.33 (P = 0.070); and week 24, 2.98 ± 1.44 mL/min/1.73 m2 (P = 0.039)]. This effect was seen in all pre-specified subgroups (P > 0.20 for interactions). No interaction between the favourable effects of FCM and baseline renal function was seen for the primary endpoints [improvement in Patient Global Assessment (P = 0.43) and NYHA class (P = 0.37) at 24 weeks]. Safety and adverse event profiles were similar in patients with baseline eGFR <60 and ≥60 mL/min/1.73 m2.

Conclusions: Treatment of iron deficiency in CHF patients with i.v. FCM was associated with an improvement in renal function. FCM therapy was effective and safe in CHF patients with renal dysfunction.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Greenlaw, Miss Nicola and Ford, Professor Ian
Authors: Ponikowski, P., Filippatos, G., Colet, J. C., Willenheimer, R., Dickstein, K., Lüscher, T., Gaudesius, G., von Eisenhart Rothe, B., Mori, C., Greenlaw, N., Ford, I., Macdougall, I., and Anker, S. D.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:European Journal of Heart Failure
Publisher:John Wiley & Sons Ltd.
ISSN:1388-9842
ISSN (Online):1879-0844
Copyright Holders:Copyright © 2015 The Authors
First Published:First published in European Journal of Heart Failure 17(3):329-339
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record